EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Standard
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. / European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.
In: J HEPATOL, Vol. 67, No. 1, 07.2017, p. 145-172.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
AU - European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
N1 - Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
PY - 2017/7
Y1 - 2017/7
N2 - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
AB - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
KW - Cholangitis
KW - Female
KW - Humans
KW - Liver Transplantation
KW - Male
KW - Practice Guidelines as Topic
KW - Prognosis
KW - Ursodeoxycholic Acid
KW - Journal Article
U2 - 10.1016/j.jhep.2017.03.022
DO - 10.1016/j.jhep.2017.03.022
M3 - SCORING: Journal article
C2 - 28427765
VL - 67
SP - 145
EP - 172
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 1
ER -